Terms: = Kidney tumors AND CD52, CDW52, EDDM5 AND Treatment
4 results:
1. Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation.
van den Hoogen MW; Hoitsma AJ; Hilbrands LB
Expert Opin Biol Ther; 2012 Aug; 12(8):1031-42. PubMed ID: 22583145
[TBL] [Abstract] [Full Text] [Related]
2. Depletion of alloreactive T cells for tolerance induction in a recipient of kidney and hematopoietic stem cell transplantations.
Tangnararatchakit K; Tirapanich W; Anurathapan U; Tapaneya-Olarn W; Pakakasama S; Jootar S; Slavin S; Hongeng S
Pediatr Transplant; 2012 Dec; 16(8):E342-7. PubMed ID: 22553996
[TBL] [Abstract] [Full Text] [Related]
3. Anti-CD45 and anti-cd52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
[TBL] [Abstract] [Full Text] [Related]
4. Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H.
Hutchins JT; Kull FC; Bynum J; Knick VC; Thurmond LM; Ray P
Proc Natl Acad Sci U S A; 1995 Dec; 92(26):11980-4. PubMed ID: 8618827
[TBL] [Abstract] [Full Text] [Related]
